LGT Capital Partners’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-55,000
| Closed | -$284K | – | 61 |
|
|
2024
Q2 | $284K | Hold |
55,000
| – | – | 0.01% | 58 |
|
|
2024
Q1 | $294K | Hold |
55,000
| – | – | 0.01% | 57 |
|
|
2023
Q4 | $428K | Hold |
55,000
| – | – | 0.01% | 60 |
|
|
2023
Q3 | $217K | Hold |
55,000
| – | – | 0.01% | 63 |
|
|
2023
Q2 | $173K | Hold |
55,000
| – | – | 0.01% | 64 |
|
|
2023
Q1 | $147K | Hold |
55,000
| – | – | ﹤0.01% | 65 |
|
|
2022
Q4 | $197K | Hold |
55,000
| – | – | 0.01% | 63 |
|
|
2022
Q3 | $354K | Hold |
55,000
| – | – | 0.01% | 66 |
|
|
2022
Q2 | $529K | Buy |
55,000
+5,000
| +10% | +$48.1K | 0.02% | 65 |
|
|
2022
Q1 | $595K | Hold |
50,000
| – | – | 0.02% | 70 |
|
|
2021
Q4 | $1.63M | Buy |
50,000
+45,661
| +1,052% | +$1.49M | 0.04% | 72 |
|
|
2021
Q3 | $194K | Buy |
+4,339
| New | +$194K | 0.01% | 73 |
|